Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
SK Square’s subsidiary SK Hynix reported that an employee who had been undergoing medical treatment after receiving approval for an occupational illness in March 2025 passed away on June 25, 2026.
📊 [Summary of Key Disclosure Facts & Figures]
1. Industrial Accident Overview
- Disclosure Type: Occurrence of Serious Industrial Accident (Major Management Matter of Subsidiary)
- Subsidiary Name: SK Hynix Inc.
- Location of Occurrence: Medical Treatment Hospital of the Victim
- Accident Details: Death on June 25, 2026, during medical treatment following approval of occupational illness under Industrial Accident Compensation Insurance Act on March 5, 2025
- Casualties: 1 Fatality / 0 Injured
2. Key Dates
- Date of Occurrence: 2026-06-25
- Date of Report to Ministry of Employment & Labor: 2026-06-26
3. Measures Taken & Key Notes
- Measures & Future Plans: On-site investigation and cause determination by the Ministry of Employment and Labor planned.
- Other Investment Notes: Whether the incident constitutes a serious accident under the Occupational Safety and Health Act is not yet confirmed; an amended disclosure will be submitted once investigation findings are verified.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Ministry Investigation Findings and Statutory Status
This filing notifies the death of an SK Hynix employee during medical treatment as a major management matter of a subsidiary. As the official determination of whether this constitutes a serious industrial accident under relevant safety laws depends on the Ministry of Employment and Labor’s investigation, monitoring for subsequent amended disclosures is recommended.
📢 Disclaimer & Source Information
Source: This content was newly structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Disclaimer: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
